Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10609772 | 0.89 | CA4 (0.40) | — | |
| Hydrochloric Acid SCHEMBL8556635 | 0.89 | CA4 (0.40) | — | |
| Hydrochloric Acid SCHEMBL11396330 | 0.87 | CA4 (0.67) | — | |
| Hydrochloric Acid SCHEMBL3896226 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL446648 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL344232 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL10940122 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL28508184 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL439803 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL9644720 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155816-B2 | Oligonucleotide conjugates | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2021-10-26 | — | — | US | disclosed |
| US-20210238601-A1 | Oligonucleotide Conjugates | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2021-08-05 | — | — | US | disclosed |
| CN-110459328-B | Clinical monitoring equipment | 浙江大学 | 2020-07-28 | — | — | CN | disclosed |
| EP-3406718-A1 | OLIGONUCLEOTIDE CONJUGATES | Roche Innovation Center Copenhagen A/S (DK) | 2018-11-28 | — | — | EP | disclosed |
| US-10077443-B2 | Oligonucleotide conjugates | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2018-09-18 | — | — | US | disclosed |
| US-20180251764-A1 | Oligonucleotide Conjugates | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2018-09-06 | — | — | US | disclosed |
| EP-2920307-B1 | ANTI APOB ANTISENSE CONJUGATE COMPOUNDS | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2018-05-02 | — | — | EP | disclosed |
| US-20160289677-A1 | APOB Antisense Conjugate Compounds | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2016-10-06 | — | — | US | disclosed |
| EP-3068885-A1 | APOB ANTISENSE CONJUGATE COMPOUNDS | Roche Innovation Center Copenhagen A/S (DK) | 2016-09-21 | — | — | EP | disclosed |
| US-20150368642-A1 | LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2015-12-24 | — | — | US | disclosed |
| EP-2920304-A1 | OLIGONUCLEOTIDE CONJUGATES | Roche Innovation Center Copenhagen A/S (DK) | 2015-09-23 | — | — | EP | disclosed |
| EP-2920307-A1 | ANTI APOB ANTISENSE CONJUGATE COMPOUNDS | Roche Innovation Center Copenhagen A/S (DK) | 2015-09-23 | — | — | EP | disclosed |
| WO-2015071388-A1 | APOB ANTISENSE CONJUGATE COMPOUNDS | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2015-05-21 | — | — | WO | disclosed |
| WO-2014118267-A1 | LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES | SANTARIS PHARMA A/S (DK) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014076195-A1 | OLIGONUCLEOTIDE CONJUGATES | SANTARIS PHARMA A/S (DK) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014076196-A1 | ANTI APOB ANTISENSE CONJUGATE COMPOUNDS | SANTARIS PHARMA A/S (DK) | 2014-05-22 | — | — | WO | disclosed |
| WO-2012016229-A2 | OXYTOCIN TREATMENT TO IMPROVE MEMORY AND MODIFY BLOOD GLUCOSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-02 | — | — | WO | disclosed |
| CN-101709083-B | Fibrinolytic protein from scorpion tails, preparation method and application thereof | GUANGDONG UNIVERSITY OF TECHNOLOGY (CN) | 2012-02-01 | — | — | CN | disclosed |
| CN-101709083-A | Fibrinolytic protein from scorpion tails, preparation method and application thereof | UNIV GUANGDONG TECHNOLOGY | 2010-05-19 | — | — | CN | disclosed |
| CN-101454017-A | Method for elevating prolactin in mammals | CARA THERAPEUTICS INC (US) | 2009-06-10 | — | — | CN | disclosed |